Last reviewed · How we verify
JNJ-67896049
At a glance
| Generic name | JNJ-67896049 |
|---|---|
| Also known as | Selexipag |
| Sponsor | Actelion |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension (PHASE2)
- A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option (PHASE3)
- A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension (PHASE3)
- A Study of Selexipag in Participants Who Participated in a Previous Selexipag Study (PHASE3)
- A Study of Selexipag in Healthy Male Participant (PHASE1)
- A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging (PHASE4)
- A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JNJ-67896049 CI brief — competitive landscape report
- JNJ-67896049 updates RSS · CI watch RSS
- Actelion portfolio CI